Completed Access to Information Requests

Follow:

  • RSS
  • Cite
About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 375 record(s)

Req # A-2022-001495

Adverse Drug Reactions (ADRs). Report numbers: E2B_05172969, E2B_05223762, 001001275, E2B_05627878, E2B_05766145, E2B_05797168, E2B_04659086, E2B_04737772, 000998122, E2B_05422984.

Organization: Health Canada

363 page(s)
May 2023

Req # A-2022-001513

Adverse Drug Reactions (ADRs) for ALENDRONIC ACID. Report numbers: E2B_01803976, E2B_01806955, E2B_01839494, E2B_01895557, 000721014, E2B_01835937, E2B_02275602, E2B_01898967, 000720995, E2B_02035743.

Organization: Health Canada

637 page(s)
May 2023

Req # A-2022-001517

Adverse Drug Reactions (ADRs) for VEDOLIZUMAB. Report numbers: E2B_05980473, E2B_06029464. ADRs for ONDANSETRON. Report numbers: E2B_05986311, E2B_05988217, E2B_05974379, E2B_05970800. ADR for PANTOLOC. Report number: 001022041. ADRs for MEZAVANT. Report numbers: E2B_06024257, E2B_05992334. ADR for PANTOPRAZOLE SODIUM. Report number: 001021230.

Organization: Health Canada

186 page(s)
May 2023

Req # A-2022-001519

Adverse Drug Reactions (ADRs) for MESALAZINE. Report numbers: E2B_06001907, 001022481, E2B_05992336, E2B_05996880, E2B_05975434, E2B_05992300, E2B_06029464, E2B_06004192, 001022980, 001025517.

Organization: Health Canada

68 page(s)
May 2023

Req # A-2022-001521

Adverse Drug Reactions (ADRs) for VYVANSE. Report numbers: 001022362, E2B_06007689, 001021585, 001022523. ADRs for C1 ESTERASE INHIBITOR (HUMAN). Report numbers: E2B_05981092, E2B_06009474, E2B_05986973, E2B_06029786. ADR for GAMMAGARD LIQUID. Report number: 001020081.

Organization: Health Canada

78 page(s)
May 2023

Req # A-2022-001543

Adverse Drug Reactions (ADRs). Report numbers: E2B_05995344, E2B_05998688, E2B_06025434.

Organization: Health Canada

75 page(s)
May 2023

Req # A-2022-001558

Adverse Drug Reactions (ADRs) for PATIROMER. Report numbers: E2B_06052509, E2B_06052511, E2B_06074727. ADR for VELPHORO. Report number: 001023533. ADR for ABILIFY. Report number: 001023608.

Organization: Health Canada

45 page(s)
May 2023

Req # A-2022-001582

Adverse Drug Reactions (ADRs). Report numbers: 001021984, E2B_05992367, E2B_05977360, 001023218, 001021985.

Organization: Health Canada

78 page(s)
May 2023

Req # A-2022-001603

Adverse Drug Reactions (ADRs). Report numbers: E2B_06029094, E2B_06028638, E2B_06009141, E2B_05972656, E2B_05982908, 001024270, E2B_06015264, 001022060, E2B_05979018, E2B_05977730.

Organization: Health Canada

273 page(s)
May 2023

Req # A-2022-001627

Adverse Drug Reactions (ADRs). Report numbers: E2B_05494677, E2B_06037946.

Organization: Health Canada

19 page(s)
May 2023
Date modified: